<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03587701</url>
  </required_header>
  <id_info>
    <org_study_id>18-0195</org_study_id>
    <nct_id>NCT03587701</nct_id>
  </id_info>
  <brief_title>Effects of Anakinra in Subjects With Autoimmune Inner Ear Disease</brief_title>
  <official_title>A Phase II Placebo Controlled Study of the Effects of Anakinra (Kineret) in Subjects With Corticosteroid-Resistant Meniere's Disease (CR-MD) and Corticosteroid-Resistant Autoimmune Inner Ear Disease Disease (CR-AIED)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sobi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II randomized, placebo controlled study design of anakinra (Kineret) in
      corticosteroid-resistant Meniere's disease (CR-MD)and corticosteroid-resistant autoimmune
      inner ear disease (CR-AIED) patients. Patients will be randomized by a 2:1 allocation to
      anakinra or placebo for 42 continuous days. After day 42, a second placebo-controlled period
      will begin for an additional 42 days. This will be followed by a 264 day observation period,
      during which, hearing declines may be re-treated with anakinra after 30 days following the
      initial drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be evaluating whether or not anakinra (kineret) is superior to placebo for
      improving sustained hearing thresholds in patients with CR-MD and CR-AIED. Final enrollment
      is contingent on an acute decline in hearing in the active ear and 2 sequential audiograms
      greater than or equal to 28 days apart that shows a stable or declining hearing threshold and
      word recognition score not improved with corticosteroid therapy. Anakinra (kineret)
      100mg/0.67ml prefilled syringes or placebo injection will be randomized at 2:1 allocation and
      will be self-administered by the patient daily for 42 days. After day 42, a second
      placebo-controlled period will begin for an additional 42 days (all patients will receive
      anakinra for either 42 or 84 days depending on the randomization assignment). A 264 day
      observation period will begin after day 84, during which the option to retreat with anakinra
      will be offered to those patients that responded to the therapy in the first 84 day period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study is a randomized, placebo-controlled design with a 2:1 allocation of anakinra or placebo for the first 42 continuous days. After day 42, a second placebo-controlled period will begin for an additional 42 days.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The subject, investigator and study coordinator will all be blinded to the randomization assignment. Only the study pharmacist will be unblended when dispensing the study medication</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained improvement in hearing thresholds</measure>
    <time_frame>Hearing improvement from pre-treatment thresholds at day 28</time_frame>
    <description>Determine whether those treated with anakinra demonstrate a sustained improvement in hearing thresholds compared with their pre-anakinra treatment threshold. Improvement will be defined by an improvement of 15dB at 1 frequency or 10dB at 2 contiguous frequencies with no greater than a 5dB worsening all remaining frequencies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sustained improvement in hearing thresholds</measure>
    <time_frame>Hearing improvement from pre-treatment thresholds at day 42</time_frame>
    <description>threshold. Improvement will be defined by an improvement of 15dB at 1 frequency or 10dB at 2 contiguous frequencies with no greater than a 5dB worsening all remaining frequencies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improved Word Recognition</measure>
    <time_frame>at day 28</time_frame>
    <description>Determine whether those treated with anakinra demonstrate a sustained improvement in word recognition score compared with their pre-anakinra treatment threshold. Improvement will be defined by an improvement of greater than 12% change in value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improved Word Recognition</measure>
    <time_frame>at day 42</time_frame>
    <description>Determine whether those treated with anakinra demonstrate a sustained improvement in word recognition score compared with their pre-anakinra treatment threshold. Improvement will be defined by an improvement of greater than 12% change in value</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Autoimmune Inner Ear Disease</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will be randomized to receive intervention of 42 consecutive days of anakinra (100mg/0.67ml) in period 1 followed by an additional 42 consecutive days of anakinra (100mg/0.67ml) in period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will be randomized to receive intervention of 42 consecutive days of anakinra (100 mg/0.67ml) in period 1 followed by 42 consecutive days of placebo in period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will be randomized to receive intervention of placebo for 42 consecutive days in period 1 followed by 42 consecutive days of anakinra (100mg/0.67ml) in period 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra 100Mg/0.67Ml Inj Syringe (Period 1)</intervention_name>
    <description>pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo injection (Period 1)</intervention_name>
    <description>pre-filled matching placebo injections will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra 100Mg/0.67Ml Inj Syringe (Period 2)</intervention_name>
    <description>pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo injection (Period 2)</intervention_name>
    <description>pre-filled matching placebo injections will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  meet diagnostic criteria for Autoimmune Inner Ear Disease (AIED) with active
             deterioration in one ear as defined below

          -  SNHL of greater than 30dB at one or more frequencies in the active ear. The
             contralateral ear may have any hearing threshold that is either stable or worsening,
             but may not exhibit improvement in response to corticosteroids even if the more active
             ear declines. Active deterioration is defined as a 15dB decline at one frequency
             (excluding 250 or 8kHz as a sole indicator) on their audiogram, or 10dB at 2+
             frequencies developing in &gt; or equal 3 days but &lt; or equal 90 days, or if the hearing
             loss evolved in less than 3 days, the patient displayed features suggestive of an
             autoimmune disorder

          -  Capable of understanding and giving informed consent

          -  Have 2 sequential audiograms following the decline in hearing &gt;or equal 28 days apart
             with no demonstrable improvement in hearing following corticosteroid therapy (&lt;or
             equal 5dB of improvement at any individual frequency (250, 500, 1000, 2000 and 4000Hz)
             and &lt;12% improvement in WRS)

          -  Patients must have been treated with oral prednisone within 45 days prior to trial
             enrollment, have completed a minimum of 60mg of prednisone (or equivalent) for 14 days
             with a variable taper and have completed the therapy by greater or equal to 14 days
             prior to enrollment

             -&gt; or equal to 14 days since any prior steroid usage

          -  Meniere's disease defined according to the AAO criteria, with the additional
             requirement of corticosteroid resistance AND no new diuretics may be instituted or
             dose increased from 28 days prior to trial enrollment

          -  Patients must be fluent in English as all word recognition scores are based on testing
             in English

          -  Patients may have other autoimmune disease(s) Females of childbearing potential, must
             be practicing a method of birth control considered effective and medically acceptable
             by the investigator for a minimum of 2 months prior to the study and at least 2 months
             after last administration of study drug

          -  Males similarly must be practicing a method of birth control considered effective and
             medically acceptable by the investigator for a minimum of 2 months prior to the study
             and at least 2 months after last administration of study drug

        Exclusion Criteria:

          -  Evidence of retrocochlear pathology (vestibular schwannoma) or inner ear malformation
             (Mondini Malformation or Enlarged Vestibular Aqueduct) based on imaging

          -  Prior treatment with gentamicin for Meniere's Disease

          -  Most recent decline in hearing occurring &gt;90 days prior to trial enrollment

          -  Positive test for Muckle-Wells mutation

          -  Concurrently receiving methotrexate, TNF-antagonist therapy or any other
             immunosuppressive therapy

          -  Any immunodeficiency syndrome

          -  Active or chronic infections

          -  Currently receiving, or having received treatment for a malignancy in the past 3 years

          -  Chronic renal insufficiency (a creatinine clearance of &lt;49mL/min) or chronic renal
             failure

          -  Neutropenia prior to treatment with anakinra

          -  Receipt of live vaccine &lt;3 months prior to enrollment

          -  Previous treatment with an IL-1 antagonist for any clinical indication

          -  First-degree relative with a diagnosis of a CAPS disease

          -  History of active narcotic abuts, including prescription narcotics

          -  Pregnant or lactating females

          -  Non-English speaking patients

          -  Seropositive for Hepatitis B, C, HIV or tuberculosis on screening, with the exception
             of presence of antibodies to Hepatitis B in subjects reporting prior vaccination, and
             presence of positive skin testing for TB in subjects who received BCG in the past

          -  History of suicidal ideation, significant depression that resulted in hospitalization,
             or answers &quot;yes&quot; during C-SSR screening

          -  Prior participation in any type of clinical trial using a medication that inhibits
             interleukin-1 activity

          -  Known hypersensitivity to E.coli derived products

          -  Latex sensitivity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Vambutas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ginny Mullooly, RN</last_name>
    <phone>718-470-7974</phone>
    <email>gmullool@northwell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Vambutas, MD</last_name>
    <phone>718-470-7550</phone>
    <email>avambuta@northwell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwell Health, Hearing&amp; Speech Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Vambutas, MD</last_name>
      <phone>718-470-7550</phone>
      <email>avambuta@northwell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ginny Mullooly, RN</last_name>
      <phone>718-470-7974</phone>
      <email>gmullool@northwell.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Vambutas A, Lesser M, Mullooly V, Pathak S, Zahtz G, Rosen L, Goldofsky E. Early efficacy trial of anakinra in corticosteroid-resistant autoimmune inner ear disease. J Clin Invest. 2014 Sep;124(9):4115-22. doi: 10.1172/JCI76503. Epub 2014 Aug 18.</citation>
    <PMID>25133431</PMID>
  </results_reference>
  <results_reference>
    <citation>Pathak S, Goldofsky E, Vivas EX, Bonagura VR, Vambutas A. IL-1Î² is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease. J Immunol. 2011 Feb 1;186(3):1870-9. doi: 10.4049/jimmunol.1002275. Epub 2011 Jan 3.</citation>
    <PMID>21199898</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2018</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Andrea Vambutas</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ear Diseases</mesh_term>
    <mesh_term>Labyrinth Diseases</mesh_term>
    <mesh_term>Labyrinthitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

